Literature DB >> 26584286

MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer.

Ying Chen, Yanping Gao, Kai Zhang, Chen Li, Yan Pan, Jing Chen, Rui Wang, Longbang Chen.   

Abstract

Cisplatin (CDDP) is one of the most effective broad-spectrum anticancer drugs, which has been employed for the treatment of lung cancer. The development of CDDP resistance is a major problem of tumor chemotherapy. MicroRNAs (miRNAs) are an abundant class of small non-protein-coding RNAs, involved in the initiation and progression of human cancer. Increasing evidence has shown that dysregulation of miRNAs is involved in chemo resistance of tumor cells to anti-cancer drugs, including CDDP. This article summarizes current research involving miRNAs as regulators of key target genes for CDDP resistance in lung cancer. Potential use of targeting miRNAs can lead to miRNA-based therapies, which will be helpful for overcoming drug resistance and developing more effective personalized anti-cancer treatment strategies in human lung cancers.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26584286     DOI: 10.1159/000438548

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  13 in total

1.  MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment.

Authors:  Xiaoyue Xu; Shaorong Yu; Wenbo Sun; Xiaobing Qin; Yan Chen; Leilei Zhou; Rui Lou; Shuchen Dong; Bo Shen; Jianzhong Wu; Jialan Zang; Haixia Cao; Meiqi Shi; Qin Zhang; Jifeng Feng
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-29       Impact factor: 4.553

2.  MicroRNA-424 regulates cisplatin resistance of gastric cancer by targeting SMURF1 based on GEO database and primary validation in human gastric cancer tissues.

Authors:  Li Lu; Menglin Wu; Yaoheng Lu; Zhicheng Zhao; Tong Liu; Weihua Fu; Weidong Li
Journal:  Onco Targets Ther       Date:  2019-09-17       Impact factor: 4.147

3.  Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma.

Authors:  Diego de Miguel-Pérez; Clara Isabel Bayarri-Lara; Francisco Gabriel Ortega; Alessandro Russo; María José Moyano Rodriguez; Maria Jesus Alvarez-Cubero; Elizabeth Maza Serrano; José Antonio Lorente; Christian Rolfo; María José Serrano
Journal:  Cancers (Basel)       Date:  2019-11-07       Impact factor: 6.639

4.  Knockdown of Long Non-Coding RNA HOTAIR Suppresses Cisplatin Resistance, Cell Proliferation, Migration and Invasion of DDP-Resistant NSCLC Cells by Targeting miR-149-5p/Doublecortin-Like Kinase 1 Axis.

Authors:  Yiyi Zhan; Kahaerjiang Abuduwaili; Xiuli Wang; Yanli Shen; Saiteer Nuerlan; Chunling Liu
Journal:  Cancer Manag Res       Date:  2020-08-24       Impact factor: 3.989

5.  Silencing of TGIF sensitizes MDA-MB-231 human breast cancer cells to cisplatin-induced apoptosis.

Authors:  Teng Pan; Tingting Mao; Haiyan Yang; Haiyu Wang; Yadong Wang
Journal:  Exp Ther Med       Date:  2018-01-19       Impact factor: 2.447

Review 6.  MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas.

Authors:  Irina Fadejeva; Horst Olschewski; Andelko Hrzenjak
Journal:  Oncotarget       Date:  2017-12-05

7.  MALAT1-miR-101-SOX9 feedback loop modulates the chemo-resistance of lung cancer cell to DDP via Wnt signaling pathway.

Authors:  Wei Chen; Wei Zhao; Li Zhang; Lixin Wang; Jipeng Wang; Zongren Wan; Yongqing Hong; Liang Yu
Journal:  Oncotarget       Date:  2017-10-09

8.  Baicalein inhibits cell growth and increases cisplatin sensitivity of A549 and H460 cells via miR-424-3p and targeting PTEN/PI3K/Akt pathway.

Authors:  Chunya Lu; Huaqi Wang; Shanshan Chen; Rui Yang; Hui Li; Guojun Zhang
Journal:  J Cell Mol Med       Date:  2018-02-01       Impact factor: 5.310

9.  miR-206 Promotes Cancer Progression by Targeting Full-Length Neurokinin-1 Receptor in Breast Cancer.

Authors:  Yu Zhou; Meng Wang; Yingna Tong; Xiaobin Liu; Lufang Zhang; Dong Dong; Jie Shao; Yunli Zhou
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

10.  miR-34c Targets MET to Improve the Anti-Tumor Effect of Cisplatin on Ovarian Cancer.

Authors:  Shiying Yang; Zhen Li; Rui Luo
Journal:  Onco Targets Ther       Date:  2020-04-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.